The most commonly reported side effects of eribulin include neutropenia, malignant neoplasm progression, and myelosuppression, based on 6,604 FDA adverse event reports from 2010 to 2025.
Percentages show how often each reaction appears relative to total reports for eribulin.
These are voluntary reports and do not establish that eribulin caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside eribulin. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
89.2% of eribulin adverse event reports involve female patients and 5.8% involve male patients. The largest age group is adult at 70%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking eribulin when the adverse event was reported.
Showing 15 of 295 indications
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.